Day: December 22, 2020

The Noteholders’ Meeting of the bond Algowatt Tv Eur6m+1,5 Dc27 Amort – ISIN Code: IT0004991573 approves the amendment of the loan Terms and ConditionsalgoWatt S.p.A., GreenTech Solutions Company listed on the Italian Stock Exchange (MTA), announces that the bondholders’ meeting (the “Bondholders’ Meeting”) of the Algowatt Tv Eur6m+1,5 Dc27 Amort bond – ISIN Code: IT0004991573 met in first call on today, 22 December 2020 at 12 AM (CET) under the chairmanship of Stefano Neri and in the presence of Notary Dario Restuccia from Milano, was attended by bondholders representing 50,8% of the bond.The Bondholders’ Meeting resolved, with the majorities required by law, to further amend the bond Terms and Conditions and, in the immediate term, to grant a waiver to the provisions of the loan Terms...

L’Assemblea degli Obbligazionisti del bond Algowatt Tv Eur6m+1,5 Dc27 Amort – Codice ISIN: IT0004991573 approva la modifica del regolamento del prestito             algoWatt S.p.A., GreenTech Solutions Company quotata sul mercato telematico azionario (MTA) di Borsa Italiana, comunica che l’assemblea degli obbligazionisti (l’“Assemblea degli Obbligazionisti”) del prestito obbligazionario Algowatt Tv Eur6m+1,5 Dc27 Amort – Codice ISIN: IT0004991573 riunitasi con la presidenza di Stefano Neri e agli atti del Notaio Dario Restuccia di Milano, in prima convocazione, in data odierna, 22 dicembre 2020 alle ore 12.00, ha visto la presenza di obbligazionisti rappresentanti il 50,8% del bond.L’Assemblea degli Obbligazionisti ha deliberato, con le maggioranze previste dalla legge, una ulteriore modifica del regolamento del prestito obbligazionario,...

Fuel4Thought™ proprietary Migraine formulation is similar to their recently released Brain Booster, but scientifically designed to try and provide millions of sufferers a natural solution.LAS VEGAS, Dec. 22, 2020 (GLOBE NEWSWIRE) — Grey Cloak Tech Inc. (OTCQB: GRCK) – (soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary development of natural plant-based formulations as well as sales and distribution of cardiovascular and neuro products, is pleased to announce its subsidiary, Ultimate Brain Nutrients™, (UBN) has announced a successful completion of a pilot study for its proprietary Fuel4Thought™ (F4T™) formulation to help with Migraines.Dr. Gerald Haase, MD. a key consultant to the Medical Advisory Board said, “We were excited to study this unique F4T™ formulation, as previous scientific...

CHARLOTTE, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) — Extended Stay America, Inc. and ESH Hospitality, Inc. (NASDAQ:STAY) (together, the “Company”) today announced that ESH Hospitality, Inc.’s Board of Directors has declared a special cash distribution of $0.35 per share to holders of ESH Hospitality, Inc.’s Class A and B common stock. This distribution will be payable on January 20, 2021 to shareholders of record as of January 6, 2021. Additionally, the Company re-affirms its fourth quarter and full year 2020 guidance previously issued on November 9, 2020.Extended Stay America’s President and Chief Executive Officer, Bruce Haase, commented, “We are pleased our strong performance during the pandemic has enabled us to continue to return capital to shareholders, with approximately $138 million returned to paired shareholders in 2020 inclusive...

TORONTO, Dec. 22, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to report prospecting and drilling results from recent exploration at the Valentine Gold Project, central Newfoundland (the “Project”). These latest results represent fire assay data from six grab samples collected from trenches and fourteen drill holes located at the Narrows Prospect, a new greenfield area of exploration located approximately 2 kilometres northeast of the Project’s Marathon Deposit (Figure 1).As part of the 2020 exploration program at the Valentine Gold Project, 250 metres of exploration trenching was completed in the Narrows area based on encouraging surface prospecting that had been conducted in previous field seasons. The trenching was located within quartz-eye porphyry hanging wall rocks adjacent...

HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company is participating in Biotech Showcase Digital and BIO @ JPM. Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.Details of the events are as follows:During both events, members of the Salarius management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Salarius’ business and highlight recent corporate achievements, as well as anticipated milestones in the clinical programs for seclidemstat. Seclidemstat is a reversible LSD1 inhibitor being studied...

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce recent published findings in the high-impact journal, Proceedings of the National Academy of Sciences (PNAS), that further supports other 2020 publications and provides new evidence for the therapeutic potential of BET inhibitors in the treatment of COVID-19. A publication titled: “Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2”, highlights the important role that host cell receptors play in enabling viral entry into cells, and presents direct evidence that BET inhibitors reduce SARS-CoV-2 (the scientific name for the virus responsible for COVID-19) infection by inhibiting the expression of these receptors. The publication also acknowledges Resverlogix and the Company’s...